Genomic Analysis Identifies Potential Diagnostic Biomarkers for Chronic Thromboembolic Pulmonary Hypertension
Researchers have identified FOS and CD163 as potential diagnostic biomarkers for chronic thromboembolic pulmonary hypertension using single-cell and bulk RNA sequencing.
Key points
- FOS and CD163 identified as candidate diagnostic biomarkers for CTEPH
- Study combined bulk and single-cell RNA sequencing methods
- Findings remain computational and require extensive experimental validation
A recent study published in Nature Health Sciences explored the role of phagocytosis-regulating factors in chronic thromboembolic pulmonary hypertension (CTEPH), a progressive vascular condition characterized by persistent pulmonary hypertension and organized blood clots. Investigators from the Second Hospital of Hebei Medical University combined an in-house bulk RNA-sequencing cohort of eight CTEPH and eight chronic thromboembolic pulmonary disease patients with public single-cell datasets. By applying high-dimensional weighted gene co-expression network analysis and machine learning techniques, the team evaluated mononuclear phagocytes and identified 12 candidate genes linked to phagocytosis regulation.
Further screening narrowed the candidates down to two genes, FOS and CD163, both of which exhibited reduced expression in the analyzed CTEPH samples. These findings were validated using reverse transcription quantitative polymerase chain reaction. Computational modeling suggested that the downregulation of these biomarkers may relate to alterations in mononuclear phagocyte communication and functional states, particularly concerning platelet activation and neutrophil degranulation pathways. A predictive compound, CID:71,703,489, was also identified as capable of binding both biomarkers in simulations.
The authors note that these observations rely heavily on computational inferences and exploratory clinical cohorts, meaning they require robust experimental validation before any clinical application. Because the investigation is early-stage and observational, it cannot establish direct causation or guarantee diagnostic utility in broader populations. Readers should consult a qualified healthcare provider regarding any cardiovascular or pulmonary medical concerns.
What to know: FOS and CD163 were identified as downregulated candidate biomarkers in CTEPH through genomic sequencing, though further validation is necessary.
Source Nature Health Sciences — nature.com/articles/s41598-026-78631-x ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…